Mexico City / 08/20/2021 05:30:45
The pharmaceutical group Anglo-Swedish AstraZeneca announced on Friday encouraging results of a COVID-19 treatment that allows to significantly reduce the risk of developing a shape symptomatic of the disease in fragile patients.
This treatment with antibodies, whose name in cwash is AZD7442, it had not previously been shown to be effective in people who were already exposed to the virus.
But by administering it before coming into contact with the virus, the results are there, AstraZeneca explains in a statement.
In this case, it reduces the risk of developing a symptomatic form by 77%, based on data from phase 3, that is, large-scale clinical trials designed to measure its safety and efficacy.
AstraZeneca even indicates that there have been no serious cases of covid-19 or death. In these trials, carried out in Spain, France, Belgium, United Kingdom and United States, 5,197 people participated, of which 75% had comorbidities. The treatment was administered intramuscularly.
“With these tremendous results, AZD7442 could be an important tool in our arsenal to help people who may need more than a vaccine to regain a normal life.” said Myron Levin, a professor at the University of Colorado in the United States who was in charge of the trials.
“We need other approaches for people who are not well protected by covid-19 vaccines,” added Mene Pangalos, a senior official at AstraZeneca, who promised to release additional data on the trials later this year.
The laboratory specifies that it will send a file to the health authorities to obtain an emergency use or a validation in the conditions of the treatment, whose development is financed by the United States government.
AstraZeneca It was also one of the first to validate its COVID-19 vaccine, which however raised questions due to the very rare side effects, prompting countries to limit its use.
Additionally, an Oxford University study presented Thursday revealed that the Pfizer / BioNtech vaccine is more effective in fighting infections related to the delta variant of the coronavirus, but that its effectiveness decreases faster than that of the Oxford / AstraZeneca vaccine.